Lophius Biosciences appoints co-CEO to drive growth
This article was originally published in Clinica
Lophius Biosciences, a specialist in T cell-based research tools and diagnostics for functional assessment of pathogen/disease-reactive T cells, has appointed Bernd Merkl co-CEO. He was formerly the site and product management leader of Thermo Fisher Scientific’s GeneArt Centre of Excellence for Synthetic Biology. Working alongside Regensburg, Germany-based Lophius’ current CEO, Robert Phelps, Merkl will focus on the commercial operations including all marketing and sales activities. Lophius’ flagship product is T-Track CMV, a diagnostic system intended to determine the functionality of the cell-mediated immune response in cytomegalovirus seropositive transplant patients who undergo an immunosuppressive therapy.